Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ajmaline→

Ajmaline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
4360-12-7
Molecular formula
C20H26N2O2
Molecular weight
326.4 g/mol
Drug class
Class IA antiarrhythmicvoltage-gated sodium-channel blocker
Mechanism of action
A class IA antiarrhythmic that blocks cardiac voltage-gated sodium channels and alters cardiac action-potential conduction and threshold.
Indications / reported uses
  • Cardiac arrhythmias
  • Pharmacological provocation testing in selected patients with suspected Brugada syndrome

Sources: NCBI MeSH · GeneReviews (Brugada syndrome)

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ajmaline Environmental Risk Assessment (ERA) (the Ajmaline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.